ELYSIUM THERAPEUTICS, INC.
XpiRx™ technology: a novel molecular deactivation formulation that causes prescription opioids to irreversibly lose potency after their prescribed-use period
- Sector
- Biotech
- Headquarters
- AKRON, OH
- Founded
- 2013
- Latest Form D
- $915K, Nov 2020
- Total capital
- $9M
- Federal grants
- $6.3M
- 9 awards · 2015–2019
- Rank in peer group#110 of 514
- Private capital raised
- $2.7M
- 4 Form D · last Nov 2020
- 71 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 8
- 26 pending · first 2017
- Rank in peer group#40 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$915K
- Federal grantHealth and Human S · Phase II · Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids$990K
- Private capital raisedForm D · SEC · 3rd filing$215K
- Private capital raisedForm D · SEC · 2nd filing$932K
- Federal grantHealth and Human S · Phase II · Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids$985K
- Federal grantHealth and Human S · Phase I · Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods$50K
- Federal grantHealth and Human S · Phase I · Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods$225K
- Private capital raisedForm D · SEC · 1st filing$652K
Show 5 earlier federal awards
- Federal grantHealth and Human S · Phase II · Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids$987K
- Federal grantHealth and Human S · Phase II · Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs$355K
- Federal grantHealth and Human S · Phase II · Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs$5K
- Federal grantHealth and Human S · Phase II · Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs$1.1M
- Federal grantHealth and Human S · Phase II · Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance$1.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
34months
from ELYSIUM THERAPEUTICS, INC.’s first federal award to its first private round.
- First federal award · Feb 2015
- Health and Human S · $1.5M
- First Form D · Dec 2017
- $652K · 1st Form D
- Awards before first raise
- 5 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#110 · top 21%
- Granted patents#40 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Thomas Gregory JenkinsResearcherDirectorLinked by 6 patents · $6.3M in grants as PI
- Alex Gregory SturmerExecutive Officer, DirectorNamed in SEC Form D filings
- Bob E. RappaportDirectorNamed in SEC Form D filings
- Carey Gregory NgDirectorNamed in SEC Form D filings
- James Gregory HackworthDirectorNamed in SEC Form D filings
- Kathy E. LaPorteDirectorNamed in SEC Form D filings
What it has protected
USPTO · 8 granted of 34- PendingPolysubunit Opioid Prodrugs Resistant To Overdose And AbuseUSPTOApplication 19027484
- PendingPolysubunit Opioid Prodrugs Resistant To Overdose And AbuseUSPTOApplication 18528195
- PendingPolysubunit Opioid Prodrugs Resistant To Overdose And AbuseUSPTOApplication 18526595
Show all 34 patent records
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseMay 22, 2025 · Application 19027484Pending
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseNov 28, 2024 · Application 18528195Pending
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseMay 23, 2024 · Application 18526595Pending
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseAug 3, 2023 · Application 17884305Pending
- Diversion-resistant Opioid FormulationsMay 3, 2022 · US 11,318,132Granted
- Opioid Compositions Resistant To Overdose And AbuseFeb 24, 2022 · Application 17475224Pending
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseDec 14, 2021 · US 11,197,933Granted
- Opioid Compositions Resistant To Overdose And AbuseOct 26, 2021 · US 11,154,549Granted
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseSep 28, 2021 · US 11,129,825Granted
- Opioid Compositions Resistant To Overdose And AbuseJul 2, 2019 · US 10,335,406Granted
- Diversion-resistant Opioid FormulationsJun 11, 2019 · US 10,314,839Granted
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseApr 9, 2019 · US 10,251,878Granted
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseNov 7, 2017 · US 9,808,452Granted
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseApplication 62473153Pending
- Opioid Antagonist, Agonist, And Partial Agonist Prodrug Formulations And Uses ThereofApplication PCTUS2026013107Pending
- Opioid Antagonist, Agonist, And Partial Agonist Prodrug Formulations And Uses ThereofApplication 63907685Pending
- Opioid Antagonist, Agonist, And Partial Agonist Prodrug Formulations And Uses ThereofApplication 63751406Pending
- Opioid Compositions Resistant To Overdose And AbuseApplication 62413913Pending
- Diversion-resistant Opioid FormulationsApplication PCTUS2015056514Pending
- Polysubstrate Opioid AnalogsApplication 62236048Pending
- Dosing Of Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseApplication PCTUS2025015256Pending
- Diversion-resistant Opioid FormulationsApplication 62066221Pending
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseApplication 18798012Pending
- Dosing of Polysubunit Opioid Prodrugs Resistant to Overdose and AbuseApplication 63634039Pending
- Dosing of Polysubunit Opioid Prodrugs Resistant to Overdose and AbuseApplication 63632294Pending
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseApplication 18295177Pending
- Opioid Antagonist Prodrugs And Formulations For The Reversal Of Opioid OverdosesApplication PCTUS2023064757Pending
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseApplication 18187636Pending
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseApplication 17894046Pending
- Opioid Antagonist Prodrugs And Formulations For The Reversal Of Opioid OverdosesApplication 63322553Pending
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseApplication 17468306Pending
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseApplication 17407037Pending
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseApplication PCTUS2018022986Pending
- Polysubunit Opioid Prodrugs Resistant To Overdose And AbuseApplication 62479014Pending
Related companies, and why
- ADRX, INC.Similar federal contract value in Biotech · null in contracts
- TRANSCODE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- 1910 GENETICS INC.Similar federal contract value in Biotech · null in contracts
- BLACKFYNN, INC.Similar federal contract value in Biotech · null in contracts
- Theratome Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Blue Oak Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .